α-Synuclein and DJ-1 as Potential Biological Fluid Biomarkers for Parkinson’s Disease
Abstract
:1. Introduction
2. Evaluation of CSF and Blood α-Synuclein as a Biomarker of PD
3. Evaluation of CSF and Blood DJ-1 as a Biomarker of PD
4. Other Potential Blood Biomarkers for PD
5. Conclusions
Acknowledgments
References
- Humphrey, PA; Andriole, GL. Prostate cancer diagnosis. Mo. Med 2010, 107, 107–112. [Google Scholar]
- Saudek, CD; Derr, RL; Kalyani, RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA 2006, 295, 1688–1697. [Google Scholar]
- Trojanowski, JQ; Vandeerstichele, H; Korecka, M; Clark, CM; Aisen, PS; Petersen, RC; Blennow, K; Soares, H; Simon, A; Lewczuk, P; Dean, R; Siemers, E; Potter, WZ; Weiner, MW; Jack, CR, Jr; Jagust, W; Toga, AW; Lee, VM; Shaw, LM. Alzheimer’s Disease Neuroimaging Initiative. Update on the biomarker core of the Alzheimer’s Disease Neuroimaging Initiative subjects. Alzheimers Dement 2010, 6, 230–238. [Google Scholar]
- Martin, WR; Wieler, M; Gee, M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008, 70, 1411–1417. [Google Scholar]
- Vaillancourt, DE; Spraker, MB; Prodoehl, J; Abraham, I; Corcos, DM; Zhou, XJ; Comella, CL; Little, DM. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009, 72, 1378–1384. [Google Scholar]
- Orimo, S; Ozawa, E; Nakade, S; Sugimoto, T; Mizusawa, H. (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 1999, 67, 189–194. [Google Scholar]
- Ravina, B; Eidelberg, D; Ahlskog, JE; Albin, RL; Brooks, DJ; Carbon, M; Dhawan, V; Feigin, A; Fahn, S; Guttman, M; et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005, 64, 208–215. [Google Scholar]
- Hashimoto, M; Masliah, E. Alpha-synuclein in Lewy body disease and Alzheimer’s disease. Brain Pathol 1999, 9, 707–720. [Google Scholar]
- Hatano, T; Kubo, S; Sato, S; Hattori, N. Pathogenesis of familial Parkinson’s disease: new insights based on monogenic forms of Parkinson’s disease. J. Neurochem 2009, 111, 1075–1093. [Google Scholar]
- Zarranz, JJ; Alegre, J; Gómez-Esteban, JC; Lezcano, E; Ros, R; Ampuero, I; Vidal, L; Hoenicka, J; Rodriguez, O; Atarés, B; Llorens, V; Gomez Tortosa, E; del Ser, T; Muñoz, DG; de Yebenes, JG. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol 2004, 55, 164–173. [Google Scholar]
- Hong, Z; Shi, M; Chung, KA; Quinn, JF; Peskind, ER; Galasko, D; Jankovic, J; Zabetian, CP; Leverenz, JB; Baird, G; Montine, TJ; Hancock, AM; Hwang, H; Pan, C; Bradner, J; Kang, UJ; Jensen, PH; Zhang, J. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain 2010, 133, 713–726. [Google Scholar]
- Shi, M; Zabetian, CP; Hancock, AM; Ginghina, C; Hong, Z; Yearout, D; Chung, KA; Quinn, JF; Peskind, ER; Galasko, D; Jankovic, J; Leverenz, JB; Zhang, J. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson’s disease. Neurosci. Lett 2010, 480, 78–82. [Google Scholar]
- Mattsson, N; Zetterberg, H; Hansson, O; Andreasen, N; Parnetti, L; Jonsson, M; Herukka, SK; van der Flier, WM; Blankenstein, MA; Ewers, M; Rich, K; Kaiser, E; Verbeek, M; Tsolaki, M; Mulugeta, E; Rosén, E; Aarsland, D; Visser, PJ; Schröder, J; Marcusson, J; de Leon, M; Hampel, H; Scheltens, P; Pirttilä, T; Wallin, A; Jönhagen, ME; Minthon, L; Winblad, B; Blennow, K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009, 302, 385–393. [Google Scholar]
- Jakowec, MW; Petzinger, GM; Sastry, S; Donaldson, DM; McCormack, A; Langston, JW. The native form of alpha-synuclein is not found in the cerebrospinal fluid of patients with Parkinson’s disease or normal controls. Neurosci. Lett 1998, 253, 13–16. [Google Scholar]
- Borghi, R; Marchese, R; Negro, A; Marinelli, L; Forloni, G; Zaccheo, D; Abbruzzese, G; Tabaton, M. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson’s disease and normal subjects. Neurosci. Lett 2000, 287, 65–67. [Google Scholar]
- Ohrfelt, A; Grognet, P; Andreasen, N; Wallin, A; Vanmechelen, E; Blennow, K; Zetterberg, H. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci. Lett 2009, 450, 332–335. [Google Scholar]
- Mollenhauer, B; Cullen, V; Kahn, I; Krastins, B; Outeiro, TF; Pepivani, I; Ng, J; Schulz-Schaeffer, W; Kretzschmar, HA; McLean, PJ; Trenkwalder, C; Sarracino, DA; Vonsattel, JP; Locascio, JJ; El-Agnaf, OM; Schlossmacher, MG. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol 2008, 213, 315–325. [Google Scholar]
- Tokuda, T; Salem, SA; Allsop, D; Mizuno, T; Nakagawa, M; Qureshi, MM; Locascio, JJ; Schlossmacher, MG; El-Agnaf, OM. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. Biochem. Biophys. Res. Commun 2006, 349, 162–166. [Google Scholar]
- Lee, PH; Lee, G; Park, HJ; Bang, OY; Joo, IS; Huh, K. The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy. J. Neural Transm 2006, 113, 1435–1439. [Google Scholar]
- Li, QX; Mok, SS; Laughton, KM; McLean, CA; Cappai, R; Masters, CL; Culvenor, JG; Horne, MK. Plasma alpha-synuclein is decreased in subjects with Parkinson’s disease. Exp. Neurol 2007, 204, 583–588. [Google Scholar]
- Nakai, M; Fujita, M; Waragai, M; Sugama, S; Wei, J; Akatsu, H; Ohtaka-Maruyama, C; Okado, H; Hashimoto, M. Expression of alpha-synuclein, a presynaptic protein implicated in Parkinson’s disease, in erythropoietic lineage. Biochem. Biophys. Res. Commun 2007, 358, 104–110. [Google Scholar]
- Hashimoto, M; Yoshimoto, M; Sisk, A; Hsu, LJ; Sundsmo, M; Kittel, A; Saitoh, T; Miller, A; Masliah, E. NACP, a synaptic protein involved in Alzheimer’s disease, is differentially regulated during megakaryocyte differentiation. Biochem. Biophys. Res. Commun 1997, 237, 611–616. [Google Scholar]
- El-Agnaf, OM; Salem, SA; Paleologou, KE; Curran, MD; Gibson, MJ; Court, JA; Schlossmacher, MG; Allsop, D. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease. FASEB J 2006, 20, 419–425. [Google Scholar]
- Fujiwara, H; Hasegawa, M; Dohmae, N; Kawashima, A; Masliah, E; Goldberg, MS; Shen, J; Takio, K; Iwatsubo, T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol 2002, 4, 160–164. [Google Scholar]
- Desplats, P; Lee, HJ; Bae, EJ; Patrick, C; Rockenstein, E; Crews, L; Spencer, B; Masliah, E; Lee, SJ. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. USA 2009, 106, 13010–13015. [Google Scholar]
- Kordower, JH; Chu, Y; Hauser, RA; Freeman, TB; Olanow, CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat. Med 2008, 14, 504–506. [Google Scholar]
- Li, JY; Englund, E; Holton, JL; Soulet, D; Hagell, P; Lees, AJ; Lashley, T; Quinn, NP; Rehncrona, S; Bjorklund, A; Widner, H; Revesz, T; Lindvall, O; Brundin, P. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat. Med 2008, 14, 501–503. [Google Scholar]
- Nagakubo, D; Taira, T; Kitaura, H; Ikeda, M; Tamai, K; Iguchi-Ariga, SM; Ariga, H. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation withras. Biochem. Biophys. Res. Commun 1997, 231, 509–513. [Google Scholar]
- Ariga, H. Function of DJ-1, a causative gene for familial Parkinson’s disease. Seikagaku 2004, 76, 456–459. [Google Scholar]
- Bonifati, V; Rizzu, P; van Baren, MJ; Schaap, O; Breedveld, GJ; Krieger, E; Dekker, MC; Squitieri, F; Ibanez, P; Joosse, M; van Dongen, JW; Vanacore, N; van Swieten, JC; Brice, A; Meco, G; van Duijn, CM; Oostra, BA; Heutink, P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003, 299, 256–259. [Google Scholar]
- Kahle, PJ; Waak, J; Gasser, T. DJ-1 and prevention of oxidative stress in Parkinson’s disease and other age-related disorders. Free Radic. Biol. Med 2009, 47, 1354–1361. [Google Scholar]
- Choi, J; Sullards, MC; Olzmann, JA; Rees, HD; Weintraub, ST; Bostwick, DE; Gearing, M; Levey, AI; Chin, LS; Li, L. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J. Biol. Chem 2006, 281, 10816–10824. [Google Scholar]
- Waragai, M; Wei, J; Fujita, M; Nakai, M; Ho, GJ; Masliah, E; Akatsu, H; Yamada, T; Hashimoto, M. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson’s disease. Biochem. Biophys. Res. Commun 2006, 345, 967–972. [Google Scholar]
- Waragai, M; Nakai, M; Wei, J; Fujita, M; Mizuno, H; Ho, G; Masliah, E; Akatsu, H; Yokochi, F; Hashimoto, M. Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson’s disease. Neurosci. Lett 2007, 425, 18–22. [Google Scholar]
- Maita, C; Tsuji, S; Yabe, I; Hamada, S; Ogata, A; Maita, H; Iguchi-Ariga, SM; Sasaki, H; Ariga, H. Secretion of DJ-1 into the serum of patients with Parkinson’s disease. Neurosci. Lett 2008, 431, 86–89. [Google Scholar]
- Ooe, H; Iguchi-Ariga, SM; Ariga, H. Establishment of specific antibodies that recognize C106-oxidized DJ-1. Neurosci. Lett 2006, 404, 166–169. [Google Scholar]
- Bandopadhyay, R; Kingsbury, AE; Cookson, MR; Reid, AR; Evans, IM; Hope, AD; Pittman, AM; Lashley, T; Canet-Aviles, R; Miller, DW; McLendon, C; Strand, C; Leonard, AJ; Abou-Sleiman, PM; Healy, DG; Ariga, H; Wood, NW; de Silva, R; Revesz, T; Hardy, JA; Lees, AJ. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson’s disease. Brain 2004, 127, 420–430. [Google Scholar]
- Alam, ZI; Jenner, A; Daniel, SE; Lees, AJ; Cairns, N; Marsden, CD; Jenner, P; Halliwell, B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem 1997, 69, 1196–1203. [Google Scholar]
- Kikuchi, A; Takeda, A; Onodera, H; Kimpara, T; Hisanaga, K; Sato, N; Nunomura, A; Castellani, RJ; Perry, G; Smith, MA; Itoyama, Y. Systemic increase of oxidative nucleic acid damage in Parkinson’s disease and multiple system atrophy. Neurobiol. Dis 2002, 9, 244–248. [Google Scholar]
- Sato, S; Mizuno, Y; Hattori, N. Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology 2005, 64, 1081–1083. [Google Scholar]
- McGeer, PL; McGeer, EG. The role of the immune system in neurodegenerative disorders. Mov. Disord 1997, 12, 855–858. [Google Scholar]
- Nagatsu, T; Sawada, M. Inflammatory process in Parkinson’s disease: role for cytokines. Curr. Pharm. Des 2005, 11, 999–1016. [Google Scholar]
- Godau, J; Herfurth, M; Kattner, B; Gasser, T; Berg, D. Increased serum insulin-like growth factor 1 in early idiopathic Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 2010, 81, 536–538. [Google Scholar]
© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Waragai, M.; Sekiyama, K.; Sekigawa, A.; Takamatsu, Y.; Fujita, M.; Hashimoto, M. α-Synuclein and DJ-1 as Potential Biological Fluid Biomarkers for Parkinson’s Disease. Int. J. Mol. Sci. 2010, 11, 4257-4266. https://doi.org/10.3390/ijms11114257
Waragai M, Sekiyama K, Sekigawa A, Takamatsu Y, Fujita M, Hashimoto M. α-Synuclein and DJ-1 as Potential Biological Fluid Biomarkers for Parkinson’s Disease. International Journal of Molecular Sciences. 2010; 11(11):4257-4266. https://doi.org/10.3390/ijms11114257
Chicago/Turabian StyleWaragai, Masaaki, Kazunari Sekiyama, Akio Sekigawa, Yoshiki Takamatsu, Masayo Fujita, and Makoto Hashimoto. 2010. "α-Synuclein and DJ-1 as Potential Biological Fluid Biomarkers for Parkinson’s Disease" International Journal of Molecular Sciences 11, no. 11: 4257-4266. https://doi.org/10.3390/ijms11114257